CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

NCT06449586 · clinicaltrials.gov ↗
PHASE3
Phase
ACTIVE_NOT_RECRUITING
Status
250
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Ruijin Hospital